Eyenovia, Inc.

Greetings.

Welcome to Inovia's fourth quarter and full year 2020 earnings call. At this time, all participants are in a listen-only mode. A question and answer session will follow the formal presentation. If anyone should require operator assistance during the conference, please press star zero on your telephone keypad. Please note, this conference is being recorded. I will now turn the conference over to your host, Eric Whitmer. You may begin.

Good afternoon, everyone, and welcome to Inovia's fourth quarter 2020 earnings conference call and audio webcast. With me today are Inovia's chief executive officer and chief medical officer, Dr. Sean Yanchule, and Inovia's chief financial officer, John Gandolfo, and Inovia's chief operating officer, Michael Rowe. Earlier this afternoon, INOVIA issued a press release announcing financial results for the three and 12 months ended December 31st, 2020. We encourage everyone to read today's press release as well as INOVIA's annual report on Form 10-K for the year ending December 31st, 2020, which will be filed with the SEC within the next few days. The company's press release and annual report also will be available on Inovia's website at inovia.com. In addition, this conference call is being webcast through the company's website and will be archived for future reference. Please note that on today's call, we will be discussing investigational products which have yet to receive FDA approval. Please also note that certain information discussed on the call today is covered under the safe harbor provisions of the Private Securities Litigation Reform Act. We caution listeners that during this call, Inovia's management will be making forward-looking statements. Actual results could differ materially from those stated or implied by these forward-looking statements due to risk and uncertainties associated with the company's business. These forward-looking statements are subject to a number of risks, including risks related to fluctuations in our financial results, volatility and uncertainty in the global economy and financial markets in light of the evolving COVID-19 pandemic, our need to raise additional money to fund our operations for at least the next 12 months as a going concern, our estimates regarding the potential market opportunity for our product candidates and platform technology and potential revenue from licensing transactions, reliance on third parties, the ability of us and our partners to timely develop, implement, and maintain manufacturing, commercialization, and marketing capabilities and strategies for our product candidates, risks of our and our licensees' clinical trials, including but not limited to the cost, design, initiation, and enrollment, which could be adversely impacted by COVID-19 and resulting social distancing, timing, progress, and results of such trial trials. the potential impact of COVID-19 on our supply chain, the timing, and our licensee's ability to submit applications for, obtain, and maintain regulatory approval for our product candidates, the potential advantages of our product candidates and platform technology, the rate and degree of market acceptance and clinical utility of our product candidate and platform technology, our ability to attract and retain key personnel intellectual property risk, and other risks related in and qualified by the cautionary statements contained in INOVIA's press release and SEC filings, including its most recent annual report on Form 10-K and subsequent filings. This conference call contains time-sensitive information that is accurate only as of the date of this live broadcast, March 25, 2021. INOVIA undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date of this conference call, except as may be required by applicable securities law. With all that said, I'd like to turn the call over to Dr. Sean Ayenshulet.